Drug Profile
Imiquimod intravesicular - UroGen Pharma
Alternative Names: TMX-101; UGN 201; VesimuneLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator Telormedix
- Developer UroGen Pharma
- Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Skin disorder therapies; Small molecules
- Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Bladder cancer
Most Recent Events
- 31 Jul 2022 UroGen Pharma concludes the collaboration with MD Anderson for non clinical development of imiquimod + zalifrelimab as the research objectives achieved before July 2022
- 23 May 2022 UroGen Pharma initiates phase I trial for Bladder cancer (Combination therapy, Recurrent) in USA (Intravesicular) (NCT05375903)
- 22 Mar 2021 Phase I/II development is ongoing for non-muscle invasive Bladder cancer in Netherlands and Germany (UroGen Pharma pipeline, March 2021)